Transgene SA, a French immunotherapy company, reported that its 50-50 joint venture with Tianjin Tasly Pharma currently has three drug candidates in pre-clinical development. The two companies established the JV in 2010 with the goal of developing biologic drugs for the China market. Tasly is a TCM drug company. The JV’s lead product is TG1050, an adenovirus-based targeted immunotherapy aimed at treating chronic hepatitis B.
Help employers find you! Check out all the jobs and post your resume.
